Contract research and manufacturing services firm Syngene International Ltd on Thursday (October 23) has confirmed the expansion of its biologics facility with the addition of new antibody-drug conjugate (ADC) bioconjugation capabilities. The company plans to provide fully integrated, end-to-end services for ADCs, covering stages from discovery through GMP manufacturing.

The new suite of capabilities will accelerate development timelines by enabling both monoclonal antibody (mAb) production and GMP bioconjugation at a single site. This expansion is designed to complement Syngene’s existing commercial capabilities in payload and linker manufacturing.

Also Read: Syngene International acquires first US biologics facility in the USA

The company clarified that this investment in biocon

See Full Page